Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ACACB | O00763 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7979902 | 0.82 | LMNA (0.41) | MCL1HTTHSD17B10MEN1KMT2A | |
| SCHEMBL7009341 | 0.77 | MCL1 (0.32) | MCL1MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL11278891 | 0.77 | MCL1 (0.32) | MCL1 | |
| SCHEMBL11282459 | 0.77 | MCL1 (0.32) | MCL1 | |
| SCHEMBL11287874 | 0.77 | MCL1 (0.32) | MCL1 | |
| SCHEMBL1170737 | 0.74 | — | — | |
| SCHEMBL1336184 | 0.73 | MCL1 (0.38) | MCL1HTTHSD17B10ACACB | |
| SCHEMBL10835410 | 0.73 | KMT2A (0.37) | MCL1HTTHSD17B10MEN1KMT2A | |
| SCHEMBL11447784 | 0.72 | — | — | |
| SCHEMBL6748118 | 0.72 | LMNA (0.41) | MCL1HSD17B10ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113444086-B | Ezh2 inhibitors and uses thereof | 达纳-法伯癌症研究所股份有限公司 | 2024-04-30 | — | — | CN | disclosed |
| CN-117883308-A | Cosmetic or dermatological composition comprising a merocyanine and an oily phase comprising at least one alkyl or alkylene carbonate | 莱雅公司 | 2024-04-16 | — | — | CN | disclosed |
| CN-108697719-B | Modulators of extracellular 5' -nucleotidases and uses thereof | 艾库斯生物科学有限公司 | 2024-03-19 | — | — | CN | disclosed |
| CN-111712247-B | sGC stimulators | 塞科里昂医疗股份有限公司 | 2024-02-09 | — | — | CN | disclosed |
| CN-111646940-B | Preparation method of bosutinib intermediate | 鲁南制药集团股份有限公司 | 2024-01-30 | — | — | CN | disclosed |
| CN-116715700-A | CD73 inhibitor, preparation method and application thereof | 上海和誉生物医药科技有限公司 | 2023-09-08 | — | — | CN | disclosed |
| CN-116693541-A | Synthesis method of 4-chloro-5H-pyrrolo [3,2-D ] pyrimidine | 安徽大学 | 2023-09-05 | — | — | CN | disclosed |
| CN-113366008-B | CD73 inhibitor, preparation method and application thereof | 上海和誉生物医药科技有限公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-112851588-B | Micro-reaction system and method for continuously preparing 2-methyl-4-amino-5-cyanopyrimidine by using same | 复旦大学 | 2023-04-21 | — | — | CN | disclosed |
| US-11554355-B2 | Micro reaction system and method for preparing 2-methyl-4-amino-5-cyanopyrimidine using same | FUDAN UNIVERSITY (CN) | 2023-01-17 | — | — | US | disclosed |
| US-6288082-B1 | COMPOUNDS SUCH AS 6,7-DIETHOXY-4-(INDAN-5-YLAMINO) -QUINOLINE-3-CARBONITRILE USED AS ANTINEOPLASTIC AGENTS AND IN THE TREATMENT OF POLYCYCSTIC KIDNEY DISEASE | AMERICAN CYANAMID COMPANY | 2001-09-11 | — | — | US | disclosed |
| EP-1117659-A1 | SUBSTITUTED 3-CYANOQUINOLINES AS PROTEIN TYROSINE KINASES INHIBITORS | American Cyanamid Company (US) | 2001-07-25 | — | — | EP | disclosed |
| EP-1117649-A1 | SUBSTITUTED 3-CYANOQUINOLINES AS PROTEIN TYROSINE KINASES INHIBITORS | American Cyanamid Company (US) | 2001-07-25 | — | — | EP | disclosed |
| US-6107253-A | GOOD HERBICIDAL ACTION AND ARE TOLERABLE IN CROPS SUCH AS WHEAT OR RICE | BASF AKTIENGESELLSCHAFT (DE) | 2000-08-22 | — | — | US | disclosed |
| WO-2000018740-A1 | SUBSTITUTED 3-CYANOQUINOLINES AS PROTEIN TYROSINE KINASES INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-04-06 | — | — | WO | disclosed |
| WO-2000018761-A1 | SUBSTITUTED 3-CYANOQUINOLINES AS PROTEIN TYROSINE KINASES INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-04-06 | — | — | WO | disclosed |
| EP-0973746-A1 | SUBSTITUTED 3-CYANO QUINOLINES | American Cyanamid Company (US) | 2000-01-26 | — | — | EP | disclosed |
| US-6002008-A | Substituted 3-cyano quinolines | AMERICAN CYANAMID COMPANY | 1999-12-14 | — | — | US | disclosed |
| WO-1998043960-A1 | SUBSTITUTED 3-CYANO QUINOLINES | AMERICAN CYANAMID COMPANY (US) | 1998-10-08 | — | — | WO | disclosed |
| US-4082751-A | ANTIALLERGENS | BRISTOL-MYERS COMPANY (US) | 1978-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11554355-B2 | Micro reaction system and method for preparing 2-methyl-4-amino-5-cyanopyrimidine using same | DPYD, MCM4, UMPS | THRB 4490/4885MCL1 408/4885HTT 3581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.